THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that a Type C meeting has been scheduled with the FDA for October 15, 2007. The purpose of the meeting is to discuss clinical endpoints for future clinical trials of Repros’ drug, Androxal, in the treatment of secondary hypogonadism.
